BACKGROUND: The ability to restore cystic fibrosis transmembrane regulator (CFTR) function with effective small molecule modulators in patients with cystic fibrosis provides an opportunity to study relationships between CFTR ion channel function, organ level physiology, and clinical outcomes. METHODS: We performed a multisite, prospective, observational study of ivacaftor, prescribed in patients with the G551D-CFTR mutation. Measurements of lung mucociliary clearance (MCC) were performed before and after treatment initiation (1 and 3 months), in parallel with clinical outcome measures. RESULTS: Marked acceleration in whole lung, central lung, and peripheral lung MCC was observed 1 month after beginning ivacaftor and was sustained at 3 months. Improvements in MCC correlated with improvements in forced expiratory volume in the first second (FEV1) but not sweat chloride or symptom scores. CONCLUSIONS: Restoration of CFTR activity with ivacaftor led to significant improvements in MCC. This physiologic assessment provides a means to characterize future CFTR modulator therapies and may help to predict improvements in lung function. TRIAL REGISTRATION: ClinicialTrials.gov, NCT01521338. FUNDING: CFF Therapeutics (GOAL11K1).
BACKGROUND: The ability to restore cystic fibrosis transmembrane regulator (CFTR) function with effective small molecule modulators in patients with cystic fibrosis provides an opportunity to study relationships between CFTR ion channel function, organ level physiology, and clinical outcomes. METHODS: We performed a multisite, prospective, observational study of ivacaftor, prescribed in patients with the G551D-CFTR mutation. Measurements of lung mucociliary clearance (MCC) were performed before and after treatment initiation (1 and 3 months), in parallel with clinical outcome measures. RESULTS: Marked acceleration in whole lung, central lung, and peripheral lung MCC was observed 1 month after beginning ivacaftor and was sustained at 3 months. Improvements in MCC correlated with improvements in forced expiratory volume in the first second (FEV1) but not sweat chloride or symptom scores. CONCLUSIONS: Restoration of CFTR activity with ivacaftor led to significant improvements in MCC. This physiologic assessment provides a means to characterize future CFTR modulator therapies and may help to predict improvements in lung function. TRIAL REGISTRATION: ClinicialTrials.gov, NCT01521338. FUNDING: CFF Therapeutics (GOAL11K1).
Authors: Kris De Boeck; Anne Munck; Seth Walker; Albert Faro; Peter Hiatt; Geoffrey Gilmartin; Mark Higgins Journal: J Cyst Fibros Date: 2014-09-26 Impact factor: 5.482
Authors: Steven M Rowe; Sonya L Heltshe; Tanja Gonska; Scott H Donaldson; Drucy Borowitz; Daniel Gelfond; Scott D Sagel; Umer Khan; Nicole Mayer-Hamblett; Jill M Van Dalfsen; Elizabeth Joseloff; Bonnie W Ramsey Journal: Am J Respir Crit Care Med Date: 2014-07-15 Impact factor: 21.405
Authors: William D Bennett; Kirby L Zeman; Beth L Laube; Jihong Wu; Gail Sharpless; Peter J Mogayzel; Scott H Donaldson Journal: J Aerosol Med Pulm Drug Deliv Date: 2017-10-16 Impact factor: 2.849
Authors: Jane C Davies; Claire E Wainwright; Gerard J Canny; Mark A Chilvers; Michelle S Howenstine; Anne Munck; Jochen G Mainz; Sally Rodriguez; Haihong Li; Karl Yen; Claudia L Ordoñez; Richard Ahrens Journal: Am J Respir Crit Care Med Date: 2013-06-01 Impact factor: 21.405
Authors: Timothy E Corcoran; Alex S Huber; Michael M Myerburg; Daniel J Weiner; Landon W Locke; Ryan T Lacy; Lawrence Weber; Michael R Czachowski; Darragh J Johnston; Ashok Muthukrishnan; Alison T Lennox; Joseph M Pilewski Journal: J Aerosol Med Pulm Drug Deliv Date: 2019-04-10 Impact factor: 2.849
Authors: Dong-Jin Lim; Daniel Skinner; John Mclemore; Nick Rivers; Jeffrey Brent Elder; Mark Allen; Connor Koch; John West; Shaoyan Zhang; Harrison M Thompson; Justin P McCormick; Jessica W Grayson; Do-Yeon Cho; Bradford A Woodworth Journal: Int Forum Allergy Rhinol Date: 2019-11-06 Impact factor: 3.858
Authors: Beth L Laube; Kathryn A Carson; Christopher M Evans; Vanessa L Richardson; Gail Sharpless; Pamela L Zeitlin; Peter J Mogayzel Journal: Pediatr Pulmonol Date: 2020-05-29
Authors: Scott H Donaldson; Beth L Laube; Peter Mogayzel; Timothy E Corcoran; Joseph M Pilewski; Agathe Ceppe; Jihong Wu; Pradeep G Bhambhvani; Felix Ratjen; Scott D Sagel; J P Clancy; Steven M Rowe; William D Bennett Journal: J Cyst Fibros Date: 2021-05-31 Impact factor: 5.482
Authors: Dave P Nichols; Scott H Donaldson; Carla A Frederick; Steven D Freedman; Daniel Gelfond; Lucas R Hoffman; Andrea Kelly; Michael R Narkewicz; Jessica E Pittman; Felix Ratjen; Scott D Sagel; Margaret Rosenfeld; Sarah Jane Schwarzenberg; Pradeep K Singh; George M Solomon; Michael S Stalvey; Shannon Kirby; Jill M VanDalfsen; John P Clancy; Steven M Rowe Journal: J Cyst Fibros Date: 2021-02-19 Impact factor: 5.482
Authors: Cameron B Morrison; Kendall M Shaffer; Kenza C Araba; Matthew R Markovetz; Jason A Wykoff; Nancy L Quinney; Shuyu Hao; Martial F Delion; Alexis L Flen; Lisa C Morton; Jimmy Liao; David B Hill; Mitchell L Drumm; Wanda K O'Neal; Mehmet Kesimer; Martina Gentzsch; Camille Ehre Journal: Eur Respir J Date: 2022-02-03 Impact factor: 16.671